Int J Med Sci 2021; 18(8):1857-1865. doi:10.7150/ijms.58263 This issue Cite

Research Paper

Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma

Shuai Man, MD1#, Jie Yan, MD1#, Jie Li, MD, PhD1, Yanna Cao, MD, PhD1, Jiajian Hu, MD, PhD1, Wenchao Ma, MD, PhD2, Jianjing Liu, MD, PhD2✉, Qiang Zhao, MD, PhD1✉

1. Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
2. Department of Molecular Imaging and Nuclear Medicine, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
#These authors have contributed equally to this work.

Citation:
Man S, Yan J, Li J, Cao Y, Hu J, Ma W, Liu J, Zhao Q. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma. Int J Med Sci 2021; 18(8):1857-1865. doi:10.7150/ijms.58263. https://www.medsci.org/v18p1857.htm
Other styles

File import instruction

Abstract

Graphic abstract

Fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT has been commonly used in pediatric patients with newly diagnosed neuroblastoma (NB) for diagnosis. We retrospectively reviewed 40 pediatric patients with newly diagnosed NB who underwent 18F-FDG PET/CT. Clinicopathological factors and metabolic parameters including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) on PET/CT were evaluated as predictive factors for progression-free survival (PFS) and overall survival (OS) by univariate and multivariate analysis. Spearman rank correlation analyses were used to estimate the correlations between clinical factors and PET findings. The mean follow-up after 18F-FDG-PET/CT was 32.9 months. During the follow-up period 15 (37.5%) patients experienced progression, and 9 (22.5%) died. MTV (P=0.001) and TLG (p=0.004) remained significant predictive factors for tumor progression, along with lactate dehydrogenase (LDH), neuron-specific enolase (NSE) and bone metastasis. Univariate analysis showed that bone metastasis, LDH (>1064 IU/L), NSE (>364.4 ug/L), MTV (>191 cm3) and TLG (>341.41 g) correlated with PFS, and LDH (>1064 IU/L), NSE (>364.4 ug/L) and MTV (>191 cm3) correlated with OS (p<0.05). In multivariate analysis, MTV and bone metastasis were independent prognostic factors for PFS (p=0.001 and 0.023, respectively), and MTV remained the only independent prognostic factor for OS (p= 0.004). We also found that there were correlations between semiquantitative PET/CT parameters and clinical features in NB. Our results suggested that 18F-FDG PET/CT was a useful tool to predictive progression and to reflect tumor burden for patients with NB.

Keywords: 18F-FDG PET/CT, MTV, TLG, neuroblastoma, progression, tumor burden


Citation styles

APA
Man, S., Yan, J., Li, J., Cao, Y., Hu, J., Ma, W., Liu, J., Zhao, Q. (2021). Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma. International Journal of Medical Sciences, 18(8), 1857-1865. https://doi.org/10.7150/ijms.58263.

ACS
Man, S.; Yan, J.; Li, J.; Cao, Y.; Hu, J.; Ma, W.; Liu, J.; Zhao, Q. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma. Int. J. Med. Sci. 2021, 18 (8), 1857-1865. DOI: 10.7150/ijms.58263.

NLM
Man S, Yan J, Li J, Cao Y, Hu J, Ma W, Liu J, Zhao Q. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma. Int J Med Sci 2021; 18(8):1857-1865. doi:10.7150/ijms.58263. https://www.medsci.org/v18p1857.htm

CSE
Man S, Yan J, Li J, Cao Y, Hu J, Ma W, Liu J, Zhao Q. 2021. Value of pretreatment 18F-FDG PET/CT in prognosis and the reflection of tumor burden: a study in pediatric patients with newly diagnosed neuroblastoma. Int J Med Sci. 18(8):1857-1865.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image